Procter & Gamble (PG) Form 144: 1,000 Shares Proposed Sale ($156,460)
Form 144 notice for Procter & Gamble Company (PG) shows a proposed sale of 1,000 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $156,460.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Form 144 notice for Procter & Gamble Company (PG) shows a proposed sale of 1,000 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $156,460. The filer reports acquiring 15,811 shares as a Performance Stock Program Award from Procter & Gamble and intends the sale approximately on 08/29/2025. The filing also discloses that the filer sold 6,167 shares for gross proceeds of $969,907.53. The notice includes the signed representation that the seller is unaware of undisclosed material adverse information about the issuer.
Insights
TL;DR: Routine insider sale notice; transaction sizes are small relative to issuer's outstanding shares.
The Form 144 documents a proposed sale of 1,000 shares valued at $156,460 and recent sales of 6,167 shares for $969,907.53. With total shares outstanding stated as 2,342,371,488, these transactions represent a de minimis fraction of the company equity and do not, by themselves, imply material change to ownership or control. The acquisition date and nature (performance stock award) are disclosed, which is typical for equity compensation-driven sales. Impact on market or governance is likely negligible based on disclosed sizes.
TL;DR: Filing meets Rule 144 procedural requirements; includes standard certification about material nonpublic information.
The notice contains required elements: broker identity, share amounts, acquisition method (performance award), dates of acquisition and intended sale, and prior sales within three months. The signer affirms no undisclosed material adverse information and references trading-plan considerations consistent with Rule 10b5-1 language. From a governance perspective, disclosures are complete as presented; there is no indication of unusual timing or size that would raise compliance concerns based on the disclosed facts alone.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Procter & Gamble's (PG) Form 144 filed here report?
Which broker is handling the proposed sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.